In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis gets an option to Transgene's TG4010; option not exercised

Executive Summary

Novartis licensed the exclusive option to globally develop and market Transgene SA's (immunotherapies for cancer and infectious disease; part of Institut Merieux) TG4010 (MVAMUC1IL2). The compound is ready to begin Phase IIb/III trials as a first-line treatment for MUCI-positive non-small cell lung cancer (NSCLC) and other types of cancer.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Immuno-Oncology
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies